Alzheimer's disease: New therapies and the world market. Jean Moran, pp. 143, Price: £230. Financial Times Management Reports

1992 ◽  
Vol 7 (8) ◽  
pp. 616-616
Author(s):  
Elaine Murphy
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
World Market ◽  
New Therapies ◽  
The World

scholarly journals Ethnographic reflections on selfhood, embodiment and Alzheimer's disease

2004 ◽  
Vol 24 (6) ◽  
pp. 829-849 ◽  
Author(s):  
PIA C. KONTOS
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Care Facility ◽  
Ethnographic Study ◽  
The Body ◽  
Philosophical Tradition ◽  
Cultural Significance ◽  
Term Care ◽  
Long Term Care Facility ◽  
The World

Explicit in the current construction of Alzheimer's disease is the assumption that memory impairment caused by cognitive deficiencies leads to a steady loss of selfhood. The insistence that selfhood is the exclusive privilege of the sphere of cognition has its origins in the modern western philosophical tradition that separates mind from body, and positions the former as superior to the latter. This dichotomy suggests a fundamental passivity of the body, since it is primarily cognition that is held to be essential to selfhood. In contrast to the assumed erasure of selfhood in Alzheimer's disease, and challenging the philosophical underpinnings of this assumption, this paper presents the findings of an ethnographic study of selfhood in Alzheimer's disease in a Canadian long-term care facility. It argues and demonstrates that selfhood persists even with severe dementia, because it is an embodied dimension of human existence. Using a framework of embodiment that integrates the perspectives of Merleau-Ponty and Bourdieu, it is argued that selfhood is characterised by an observable coherence and capacity for improvisation, and sustained at a pre-reflective level by the primordial and socio-cultural significance of the body. The participants in this study interacted meaningfully with the world through their embodied way of ‘being-in-the-world’.

P3-243: The role for CSF dynabridging studies in developing new therapies for Alzheimer's disease

2009 ◽  
Vol 5 (4S_Part_14) ◽  
pp. P414-P415 ◽  
Author(s):  
Larry Ereshefsky ◽  
Stanford S. Jhee ◽  
Mark Yen ◽  
Samira V. Moran
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
New Therapies

Report of an International Psychogeriatric Association Special Meeting Work Group; Under the Cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association

1997 ◽  
Vol 9 (S1) ◽  
pp. 11-38 ◽  
Author(s):  
Barry Reisberg ◽  
Alistair Burns ◽  
Henry Brodaty ◽  
Robin Eastwood ◽  
Martin Rossor ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Current Knowledge ◽  
Work Group ◽  
Treatment Strategies ◽  
Diagnostic Procedures ◽  
World Health ◽  
Diagnostic Process ◽  
European Federation ◽  
The World

Current knowledge with respect to the diagnosis of Alzheimer's disease (AD) is reviewed. There is agreement that AD is a characteristic clinicopathologic entity that is amenable to diagnosis. The diagnosis of AD should no longer be considered one of exclusion. Rather, the diagnostic process is one of recognition of the characteristic features of AD and of conditions that can have an impact on presentation or mimic aspects of the clinicopathologic picture. The present availability of improved prognosis, management, and treatment strategies makes the proper, and state-of-the-art, diagnosis of AD a clinical imperative in all medical settings. Concurrently, information regarding the relevance and applicability of current diagnostic procedures in diverse cultural settings must continue to accrue.

scholarly journals A Systematic Review of Clinical Decision Support Systems in Alzheimer’s Disease Domain

2021 ◽  
Vol 17 (08) ◽  
pp. 74
Author(s):  
Sherimon P.C. ◽  
Vinu Sherimon ◽  
Preethii S.P. ◽  
Rahul Nair ◽  
Renchi Mathew
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Decision Support ◽  
Decision Support System ◽  
Clinical Decision Support ◽  
Support System ◽  
Clinical Decision Support System ◽  
Memory Loss ◽  
Clinical Decision ◽  
The World

Dementia is one of the major public health issues faced by the world. Alzheimer’s disease (AD) is the most common form of dementia targeting old age groups around the world. It is a neurodegenerative condition with memory loss as its early symptom. Unfortunately, there is no cure for this disease currently. So various research in the medical and technical fields are being conducted to help people with Alzheimer’s. Many studies focus on early diagnosis of Alzheimer’s disease using clinical decision support system (CDSS) so that the progression of the disease can be slowed down to a great extent. In this context, we have undertaken a research to design and implement an ontology based Clinical decision support system for Alzheimer’s disease in Sultanate of Oman. A semantic knowledgebase (ontology) will be the core component of our Clinical decision support system. The objective of this research paper is two-fold (a) review the medical aspects of Alzheimer’s disease, and (b) review the available clinical decision support system based on ontology, robotics, and mobile applications in Alzheimer domain. Research articles published during 2011- 2020 in PubMed, Google scholar, Elsevier, SpringerLink and IEEE journals were reviewed. We found that there is various clinical decision support system which can aid physicians in suggesting diagnosis, and treatment of Alzheimer’s disease.

scholarly journals Regulation of Caenorhabditis Elegans model in Alzheimer’s Disease

2020 ◽  
Vol 185 ◽  
pp. 03043
Author(s):  
Yuxuan Jing
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Caenorhabditis Elegans ◽  
Amyloid Beta ◽  
Significant Role ◽  
Tau Protein ◽  
Specific Gene ◽  
Protein Modelling ◽  
Gene Expressions ◽  
The World

Alzheimer’s disease (AD) is affecting numerous families and individuals around the world nowadays, as the exact reason is still undetermined. At this stage, developmental treatment displays a particularly significant role in relieving symptoms for the patients. Currently, the two most well-known factors that have impacts on the diagnosis of AD are the plaques and tangles formed from amyloid-beta and tau protein. Modelling for Alzheimer’s disease is essential in understanding targeted aspects of the disease, while Caenorhabditis elegans (C.elegans) was chosen as a pivotal model. C.elegans presents dramatic priorities using orthologs for the study of AD, especially in examining the formation of the deposits and the regulations of specific gene expressions that result in this abnormality. This review discusses the properties, which C.elegans shows on the study of AD, and the achievements that have been approached using this model, as well as what other models are being tested by scientists. Properties of other models, which can overwhelm C.elegans, as well as the expectations for future modelling systems on AD are examined as well.

scholarly journals Role of the oral microbiota in the development of Alzheimer’s disease

2020 ◽  
Vol 15 (4) ◽  
pp. 231-238
Author(s):  
Natalia Gavrilova ◽  
◽  
Nikita Gladyshev ◽  
Anna Kotrova ◽  
Anastasiia Morozova ◽  
...  
Keyword(s):  
Risk Factors ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Diagnosis ◽  
Oral Microbiota ◽  
Practical Application ◽  
Pathophysiological Role ◽  
The World ◽  
Important Practical Application

Dementia and, in particular, Alzheimer’s disease (AD), affects millions of people around the world and its prevalence is steadily rising annually. Some risk factors for AD, such as age, cannot be modified, while others could possibly be corrected. In recent years, many studies are tackling the problem of the oral and gut microbiota as a provoking factor for AD and other neurodegenerative diseases, but their relationship and specific pathophysiological mechanisms remain understudied. The microbiota of the oral cavity can be of particular importance due to the specificity of microorganisms and their localization, as well as the possibility of provoking neuroinflammation, which requires further study. This review covers the specific features of the oral microbiota, current views on the pathophysiological role of the oral microbiota in the development of AD, as well as the beneficial role of probiotics. The study of this issue can have an important practical application both for the early diagnosis of AD, and for its further treatment.

Sign in / Sign up

Export Citation Format

Share Document